Evidence map›Paper›PMID 25705900›Full record

ArticlePloS one2015

The α2,3-sialyltransferase encoded by myxoma virus is a virulence factor that contributes to immunosuppression.

Bérengère Boutard, Sophie Vankerckhove, Nicolas Markine-Goriaynoff, Mickaël Sarlet, Daniel Desmecht, Grant McFadden, Alain Vanderplasschen, Laurent Gillet

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Next step in the ongoing arms race between myxoma virus and wild rabbits in Australia is a novel disease phenotype.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Bérengère BoutardImmunology-Vaccinology, Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, FARAH, University of Liège, Liège, Belgium.
Sophie VankerckhoveImmunology-Vaccinology, Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, FARAH, University of Liège, Liège, Belgium.
Nicolas Markine-GoriaynoffImmunology-Vaccinology, Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, FARAH, University of Liège, Liège, Belgium.
Mickaël SarletPathology, Department of Morphology and Pathology, Faculty of Veterinary Medicine, FARAH, University of Liège, Liège, Belgium.
Daniel DesmechtPathology, Department of Morphology and Pathology, Faculty of Veterinary Medicine, FARAH, University of Liège, Liège, Belgium.
Grant McFaddenDepartment of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, Florida, United States of America.
Alain VanderplasschenImmunology-Vaccinology, Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, FARAH, University of Liège, Liège, Belgium.
Laurent GilletImmunology-Vaccinology, Department of Infectious and Parasitic Diseases, Faculty of Veterinary Medicine, FARAH, University of Liège, Liège, Belgium.
University of Liège · BEUniversity of Florida · US

Funding

Studies in Poxvirus Host Range Genes and TropismR01AI080607 · NIAID · UNIVERSITY OF FLORIDA · PI RAHMAN, MASMUDUR MOHAMMED · 2009 to 2025
$5.6M
Manipulation of inflammasomes and NF-kB signaling in human myeloid cells by MyxomR01AI100987 · NIAID · UNIVERSITY OF FLORIDA · PI MCFADDEN, GRANT · 2013 to 2017
$1.9M
NIAID NIH HHS R01 AI080607NIAID NIH HHS R01 AI100987
6 · The paper itself

Abstract

Myxoma virus (MYXV) induces a lethal disease called Myxomatosis in European rabbits. MYXV is one of the rare viruses that encodes an α2,3-sialyltransferase through its M138L gene. In this study, we showed that although the absence of the enzyme was not associated with any in vitro deficit, the M138L deficient strains are highly attenuated in vivo. Indeed, while all rabbits infected with the parental and the revertant strains died within 9 days post-infection from severe myxomatosis, all but one rabbit inoculated with the M138L deficient strains survived the infection. In primary lesions, this resistance to the infection was associated with an increased ability of innate immune cells, mostly neutrophils, to migrate to the site of virus replication at 4 days post-infection. This was followed by the development of a better specific immune response against MYXV. Indeed, at day 9 post-infection, we observed an important proliferation of lymphocytes and an intense congestion of blood vessels in lymph nodes after M138L knockouts infection. Accordingly, in these rabbits, we observed an intense mononuclear cell infiltration throughout the dermis in primary lesions and higher titers of neutralizing antibodies. Finally, this adaptive immune response provided protection to these surviving rabbits against a challenge with the MYXV WT strain. Altogether, these results show that expression of the M138L gene contributes directly or indirectly to immune evasion by MYXV. In the future, these results could help us to better understand the pathogenesis of myxomatosis but also the importance of glycans in regulation of immune responses.

Indexed as

Adaptive ImmunityAnimalsAntibodies, ViralDNA, ViralGene Knockout TechniquesHost-Pathogen InteractionsImmune ToleranceLeukocytes, MononuclearMaleMyxomatosis, InfectiousMyxoma virusRabbitsSialyltransferasesSurvival AnalysisTime FactorsViral ProteinsAntibodies, ViralDNA, ViralSialyltransferasesViral ProteinsVirulence Factors

Identifiers

PMID25705900
PMCPMC4338283
OpenAlexW2094546150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.